Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Current Assets (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Current Assets for 6 consecutive years, with $15.3 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 30.16% to $15.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.3 million through Dec 2025, up 30.16% year-over-year, with the annual reading at $15.3 million for FY2025, 30.16% up from the prior year.
  • Current Assets hit $15.3 million in Q4 2025 for Insight Molecular Diagnostics, down from $21.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $62.8 million in Q1 2021 to a low of $4.8 million in Q3 2024.
  • Historically, Current Assets has averaged $26.6 million across 5 years, with a median of $23.0 million in 2022.
  • Biggest five-year swings in Current Assets: tumbled 71.67% in 2024 and later surged 454.9% in 2025.
  • Year by year, Current Assets stood at $39.1 million in 2021, then crashed by 34.76% to $25.5 million in 2022, then plummeted by 58.11% to $10.7 million in 2023, then grew by 9.92% to $11.8 million in 2024, then soared by 30.16% to $15.3 million in 2025.
  • Business Quant data shows Current Assets for IMDX at $15.3 million in Q4 2025, $21.4 million in Q3 2025, and $26.8 million in Q2 2025.